On March 4-5, the 12th CBIC Cell Biology Industry Conference and the 3rd International Cell Therapy and Regenerative Medicine Conference was held in Chengdu. The conference was co-sponsored by Chengdu Health Commission, Sichuan Provincial Hospital Association, Chengdu High-tech Medical Association and other units, attracting top scientists, representatives of medical institutions and executives of biomedical enterprises from all over the world. We will conduct in-depth exchanges in frontier areas such as cell innovative therapy and application, cell industry diversification and application, stem cell clinical and industrial transformation, organoid clinical and transformation, and jointly explore the future development direction of the industry.

At the conference, chief scientist Professor Wang Jianxun served as the sharing guest of cell innovative therapy and application, and delivered a speech on the theme of "Research Progress of NK/CAR-NK cell therapy". Professor Wang first introduced the advantages and challenges of NK cell and CAR-NK cell therapy in detail in his speech. He pointed out that NK cells, as the core members of innate immunity, can kill tumor cells by directly dissolving and secreting cytokines, while CAR-NK cell therapy endoses NK cells with the ability to target NK cells specifically through genetic engineering, thus significantly improving the efficacy specificity of NK cells. Compared with CAR-T cell therapy, CAR-NK cell therapy has the advantages of good efficacy for hematoma, better efficacy for solid tumor, versatility of solution products, high industrial productivity, low cost, and low risk of side effects, so it has broad application prospects in the field of tumor therapy.

Professor Wang also shared Shenzhen Cell Valley's related products and core competitiveness in NK/CAR-NK cell therapy. For example, the transduction efficiency of retrovirus vectors prepared by Shenzhen Cell Valley was up to more than 70%, and the expression was stable. Cell Valley has optimized the culture process so that in vitro amplification can be up to tens of thousands of times, and enhances the persistence of CAR-NK cells by adding self-secreted/membrane-binding IL-15. These technical breakthroughs have effectively solved the limitations of low transduction efficiency, difficult production and proliferation, and poor persistence in clinical transformation of CAR-NK cells.

Professor Wang Jianxun said that Shenzhen Cell Valley will continue to deepen the field of NK and CAR-NK cell therapy, and constantly explore new technologies and new methods to provide patients with safer and more effective cell therapy solutions. At the same time, the company will also strengthen cooperation with well-known universities, medical institutions and scientific research institutions at home and abroad to jointly promote the rapid development of cell and gene therapy industry.

This speech not only demonstrated the latest research results and clinical progress of Shenzhen Cell Valley in the field of NK and CAR-NK cell therapy, but also further enhanced the company's visibility and influence in the industry. In the future, Shenzhen Cell Valley will continue to adhere to the development concept of "innovation, collaboration and win-win" and make greater contributions to the prosperity and development of the cell and gene therapy industry.